南京招聘

工作职责:

Produce specific Publication Plans for assigned therapeutic products

data generation programs and manage execution of publication plan.:

? Develop and execute the publication (abstract/ manu"script") plan for assigned therapeutic products aligned with the medical plan and brand plan.

? Incorporate plans into a regularly updated database and track and update key stakeholders.

? Manage external publications agencies, including medical writers to develop timelines and manage the process for development, review, approval and submission of publications.

? Ensure that publications are developed in compliance with company guidelines and SOPs.

Liaise with Life Cycle, Medical and Business/Commercial Teams, Public Relations and other functions to ensure proper internal communication on publication related competitive intelligence and upcoming publications/ presentations.:

? Establishes, maintains, and expands business relationships with all functional areas collaborating on projects.

? Deliver appropriate training to cross-functional team member to improve their competency on publication

Manage annual publications budgets:

? Develop publication budget plan liaise with brand budget plan and align with key stakeholders

? Monthly review and tracking China publication budget to identify potential variation to phasing

? Ensure variation of actual cost versus budget plan under control.

任职资格:

? High standard of integrity, life scientific/medical knowledge in the specified therapy areas

? Good interpersonal skills

? Good communication and presentation skills

? Good planning and project management skills

? Proven ability to influence and persuade

? Understanding and knowledge of key opinion leaders in specified therapy areas

? Fluent in both written and spoken English and good PC skill

信达生物成立于2011年，致力于开发、生产和销售用于治疗肿瘤等重大疾病的创新药物。2018年10月31日，信达生物制药在香港联交所主板挂牌上市，股票代码：01801。

自成立以来，公司凭借创新成果和国际化的运营模式在众多生物制药公司中脱颖而出。建立起了一条包括32个新药品种的产品链，覆盖肿瘤、代谢疾病、自身免疫等多个疾病领域，7个产品（信迪利单抗注射液，商品名：达伯舒，英文商标：TYVYT；贝伐珠单抗生物类似药，商品名：达攸同，英文商标：BYVASDA；阿达木单抗生物类似药，商品名：苏立信，英文商标：SULINNO；利妥昔单抗生物类似药，商品名：达伯华，英文商标：HALPRYZA；pemigatinib口服抑制剂，商品名：達伯坦，英文商标：PEMAZYRE；奥雷巴替尼片，商品名：耐立克；雷莫西尤单抗，商品名：希冉择，英文商标：CYRAMZA）获得批准上市， 1个品种在NMPA审评中，另外还有19个产品已进入临床研究。

信达生物已组建了一支具有国际先进水平的高端生物药开发、产业化人才团队，包括众多海归专家，并与美国礼来制药、Adimab、Incyte、MD Anderson 癌症中心和韩国Hanmi等国际合作方达成战略合作。信达生物希望和大家一起努力，提高中国生物制药产业的发展水平，以满足百姓用药可及性和人民对生命健康美好愿望的追求。

“始于信，达于行”，开发出老百姓用得起的高质量生物药，是信达生物的理想和目标。